title: Temperature preconditioning is optimal at 26° C and confers additional protection to hypothermic cardioplegic ischemic arrest.
abstract: We have recently shown that brief episodes of hypothermic perfusion interspersed with periods of normothermic perfusion, referred to as temperature preconditioning (TP), are cardioprotective and can be mimicked by consecutive isoproterenol/adenosine treatment. Here we investigate the optimal temperature for TP and whether TP further enhances protection provided by hypothermic ischemia with or without polarized cardioplegic arrest. Three experimental groups of Langendorff-perfused rat hearts were used. In the first group, hearts were subjected to three episodes of hypothermic perfusion at 7, 17, 26 and 32°C during the TP protocol, followed by 30 min normothermic index ischemia and 60 min reperfusion (37°C). Protein kinase A (PKA) activity and cyclic AMP (cAMP) concentrations were measured prior to index ischemia. In the second group, TP (26°C) hearts were subjected to two hours hypothermic index ischemia at 26°C and two hours normothermic reperfusion. In the third group, TP (26°C) hearts or hearts treated with isoproterenol/adenosine (pharmacological simulation of TP) were subjected to four hours hypothermic index ischemia with procaine-induced polarized cardioplegia at 26°C followed by two hours normothermic reperfusion. Hemodynamic function recovery, lactate dehydrogenase release and infarct size were used to assess cardioprotection. TP at 26°C resulted in highest cardioprotection, increased cAMP concentration and PKA activity, while TP at 7°C exacerbated ischemia/reperfusion damage, and had no effect on cAMP concentration or PKA activity. TP at 26°C also protected hearts during hypothermic ischemia with or without polarized cardioplegia. Isoproterenol/adenosine treatment conferred additional protection similar to TP. In conclusion, the study shows that TP-induced cardioprotection is temperature dependent and is optimal at 26°C; TP confers additional protection to hypothermia and polarized cardioplegia; and that the pharmacological treatment based on the mechanism of TP (consecutive isoproterenol/adenosine treatment) is a potential cardioprotective strategy that can be used during heart surgery and transplantation.
authors: School of Biochemistry and the Bristol Heart Institute, Medical Sciences Building, University of Bristol, University Walk, Bristol, UK. I.Khaliulin@bristol.ac.uk
authors: Igor
authors: I
authors: Khaliulin
authors: Andrew P
authors: AP
authors: Halestrap
authors: M-Saadeh
authors: MS
authors: Suleiman
references: Sheng Li Xue Bao. 2004 Jun 25;56(3):389-96
references: 15224156
references: J Mol Cell Cardiol. 2007 Mar;42(3):631-42
references: 17306295
references: Eur J Cardiothorac Surg. 2004 Nov;26(5):1002-14
references: 15519196
references: J Mol Cell Cardiol. 1993 Mar;25(3):277-88
references: 8389888
references: Ann Thorac Surg. 1999 Nov;68(5):1934-41
references: 10585107
references: Ann Thorac Surg. 1999 Nov;68(5):1960-6
references: 10585111
references: Ann N Y Acad Sci. 1999 Jun 30;874:192-210
references: 10415532
references: Science. 1986 Jan 17;231(4735):234-41
references: 2417316
references: Am J Physiol Heart Circ Physiol. 2002 Jun;282(6):H1961-9
references: 12003799
references: Int J Cardiol. 2004 Nov;97(2):263-76
references: 15458694
references: Am J Physiol. 1991 Oct;261(4 Pt 2):H1005-10
references: 1928384
references: Am J Physiol. 1999 May;276(5):H1460-7
references: 10330228
references: Eur J Cardiothorac Surg. 1997 Nov;12(5):753-8
references: 9458147
references: J Thorac Cardiovasc Surg. 1980 Oct;80(4):517-26
references: 7421286
references: Circulation. 2000 Sep 5;102(10):1172-7
references: 10973848
references: Anesth Analg. 1994 Aug;79(2):212-8
references: 7639353
references: Comp Biochem Physiol B Biochem Mol Biol. 2004 Nov;139(3):469-85
references: 15544969
references: Cell Calcium. 1991 Jan;12(1):11-8
references: 1901763
references: J Physiol. 2007 Jun 15;581(Pt 3):1147-61
references: 17395631
references: Pflugers Arch. 1979 Mar 16;379(2):137-42
references: 571107
references: J Cardiovasc Electrophysiol. 2006 May;17 Suppl 1:S141-S148
references: 16686669
references: Am J Physiol. 1999 Dec;277(6):H2321-32
references: 10600852
references: J Bioenerg Biomembr. 2009 Apr;41(2):113-21
references: 19357938
references: Am J Physiol Heart Circ Physiol. 2004 Apr;286(4):H1289-99
references: 14644763
references: Cardiovasc Res. 2010 Nov 1;88(2):324-33
references: 20558443
references: Pharmacol Ther. 2010 Jul;127(1):41-52
references: 20398698
references: Ann Thorac Surg. 2009 Jan;87(1):8-10
references: 19101260
references: J Physiol. 1989 Oct;417:537-53
references: 2621609
references: Am J Physiol Heart Circ Physiol. 2005 Jun;288(6):H2620-7
references: 15653757
references: Cardiovasc Res. 2004 Feb 15;61(3):580-90
references: 14962488
references: Scand Cardiovasc J. 1999;33(2):79-87
references: 10225309